RedHill Biopharma has transferred its 70 percent ownership of Talicia to Apotex Health Corp. The deal provides RedHill Biopharma with immediate capital to prioritize its gastrointestinal and oncology portfolios.
The $18 million cash injection and $35 million milestone potential
RedHill Biopharma, which trades on the NASDAQ under the symbol RDHL, has finalized a deal to sell its majority stake in the Talicia product line to a subsidiary of Apotex Health Corp. According to the report, the transaction includes an immediate upfront cash payment of 18 million dollars. This provides the company with a significant liquidity boost as it seeks to reposition its commercial operations.
Beyond the initial payment, the agreement establishes a performance-based incentive structure. RedHill Biopharma could receive up to an additional 35 million dollars in milestone payments, provided that Talicia hits specific worldwide net sales targets.. This divestment follows a previous move by Apotex Health Corp to acquire the U.S. branded business of Cumberland Pharmaceuticals Inc, which held the remaining 30 percent of Talicia, effectively giving the Canadian firm total control of the asset.
Trading Talicia for high-value GI and oncology targets
The decision to exit the Talicia business reflects a broader trend among specialty biopharmaceutical firms to shed niche assets in favor of "blockbuster" potential in high-growth therapeutic areas. RedHill Biopharma is shifting its focus toward larger, more lucrative opportunities within the gastrointestinal (GI) and oncology sectors. Dror Ben-Asher, the CEO of RedHill Biopharma, stated that this transaction is a pivotal milestone that converts the company's stake into immediate capital to finance future commercial expansion.
By scaling its existing GI commercial franchise, RedHill Biopharma intends to pursue new, FDA-approved product opportunities. The company believes that by focusing on high-value treatments, it can accelerate its trajectory toward operational profitability and sustained revenue growth, rather than maintaining a diversified but less scalable portfolio.
From SPHK2 inhibitors to RHB-102 and Crohn's disease
While exiting Talicia, RedHill Biopharma is doubling down on a sophisticated late-stage clinical pipeline. A primary focus is a first-in-class, orally administered sphingosine kinase-2 (SPHK2) selective inhibitor. This compound is being developed for anti-inflammatory, antiviral, and anticancer activities , and has involved collaborations with academic institutions and the U.S. government for treating Ebola Virus Disease (EVD) and GI-Acute Radiation Syndrome (GI-ARS).
The company's development efforts also include RHB-102, which targets GI intolerance associated with GLP-1 and GIP receptor agonists. As reported, RHB-102 has already shown positive results in a U.S. Phase 3 study for gastritis and acute gastroenteritis , as well as a Phase 2 study for Irritable Bowel Syndrome with Diarrhea (IBS-D). additionally, RedHill Biopharma is advancing a next-generation formulation of RHB-104 for Crohn's disease and is conducting a Phase 2 study for prostate cancer in combination with darolutamide.
How Apotex will scale Talicia across the Americas
Apotex Health Corp, the largest pharmaceutical company based in Canada, is positioned to leverage its extensive distribution networks to maximize Talicia's global growth. Headquartered in Toronto with offices in India, Mexico, and the United States, Apotex specializes in a mix of biosimilars, generic drugs, and innovative branded pharmaceuticals. The integration of Talicia allows Apotex to strengthen its role as a primary partner for product acquisitions across the Americas.
Despite the clarity on the ownership transfer, several specific details remain undisclosed. The report does not specify the exact worldwide net sales figures required for RedHill Biopharma to trigger the 35 million dollars in milestone payments. Furthermore, while the company mentions a potential UK submission for treating chemotherapy-induced nausea and vomiting via RHB-102, the exact timeline for this regulatory filing remains unverified.
Comments 0